NOVARTIS

📅 Upcoming

🕒 Recent(90d)

News

• Molecular Partners to lay off up to 44% of workforce in radiotherapy pivot
  Molecular Partners plans to lay off up to 44% of its staff as it focuses its declining cash reserves on a radiotherapeutic pipeline led by an early-phase small cell lung cancer drug candidate.
  fiercebiotech · 8h ago
• Dren Bio lands $350M to push rare blood cancer therapy toward market
  After Sanofi paid $600 million in cash to acquire Dren Bio’s bispecific last year, the biotech has secured a hefty financing to fund late-stage development and commercial preparations for its lead…
  biospace · 17h ago
• LENZ cuts 75% of staff as third quarter earnings disappoint
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 22h ago
• Geron’s Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid
  Geron has discontinued a phase 3 trial of its Rytelo in JAK inhibitor-pretreated myelofibrosis after an independent data monitoring committee ruled that the study was unlikely to succeed, just as N…
  fiercebiotech · 1d ago
• Lilly shuffles business structure; Novartis writes off part of Avidity deal
  Lilly intends to merge its U.S. and international divisions when a top executive retires. Elsewhere, Astellas closed in on what it believes to be a “best-in-class” cancer immunotherapy prospect.
  biopharma_dive · 1d ago
• Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
  Merck stole the show at the European Society for Medical Oncology (ESMO) annual conference, with new data on its Moderna-partnered personalized cancer vaccine leaking prior to the presentation and…
  biospace · 2d ago
• Big Pharma is ready to strike, with J&J most likely to buy: Leerink
  The largest pharmas have a collective $188 billion in firepower to spend on M&A transactions, with all but one signaling a desire to execute, according to a new analysis from Leerink Partners.
  biospace · 2d ago
• 5 new drug launches that defied industry expectations
  A clearly superior clinical profile, reasonable pricing and easy access has helped a handful of recently approved therapies achieve impressive launches.
  biospace · 2d ago
• Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
  The disclosure makes Artiva the third company to recently report fatal events in an autoimmune cell therapy trial, following announcements from Novartis and Bristol Myers Squibb.
  biopharma_dive · 2d ago
• Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
  Novartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.
  biospace · 2d ago